Trial Filter
BETAAn intelligent search tool for clinical trials
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Eligibility Criteria
Inclusion Criteria
- 1Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.
Locations
38 sites participating in this study
The Emory Clinic
Atlanta, Georgia 30322-1013
Jonathon Cohen
Cancer Specialists, LLC
Jacksonville, Florida 32256
Ayed Ayed
Sylvester Comprehensive Cancer Center
Miami, Florida 33136-1002
Alvaro Alencar